Advances of the anti-tumor research of metformin.
- Author:
Chao-jun XUE
;
Ke-xin LIU
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Diabetes Mellitus, Type 2;
Humans;
Hyperglycemia;
Metformin;
therapeutic use;
Neoplasms;
drug therapy
- From:
Acta Pharmaceutica Sinica
2015;50(10):1210-1216
- CountryChina
- Language:Chinese
-
Abstract:
Metformin is the most commonly prescibed drug for type 2 diabetes mellitus as it is inexpensive, safe, and efficient in ameliorating hyperglycemia and hyperinsulinemia. Numerous epidemiological studies indicate that diabetic population is not only at increased risk of cardiovascular complications, but also at substantially higher risk of many forms of malignancies. Meanwhile, epidemiological and clinical observation studies have shown that metformin use reduces risk of cancer in patients with type 2 diabetes mellitus and improves prognosis and survival rate of the cancer patients. Furthermore, metformin has been used for cancer therapy in clinical trials. Thus, metformin is emerging as a new cancer therapy or adjuvant anticancer drugs. This review summarizes recent progress in studies of metformin use and its molecular mechanism.
